Abbott Laboratories vs Merck Indonesia Which Is Stronger?

Abbott Laboratories and Merck Indonesia are both prominent players in the pharmaceutical industry, with a strong presence in the global market. Abbott Laboratories, a US-based company, is known for its diverse portfolio of healthcare products and has consistently delivered strong financial performance. On the other hand, Merck Indonesia is a subsidiary of the multinational pharmaceutical giant Merck & Co., Inc., headquartered in the US. Both companies have a solid track record of innovation and growth, making them attractive investment options for those looking to invest in the pharmaceutical sector.

Abbott Laboratories or Merck Indonesia?

When comparing Abbott Laboratories and Merck Indonesia, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Abbott Laboratories and Merck Indonesia.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Abbott Laboratories has a dividend yield of 2.35%, while Merck Indonesia has a dividend yield of 9.17%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Abbott Laboratories reports a 5-year dividend growth of 12.74% year and a payout ratio of 48.66%. On the other hand, Merck Indonesia reports a 5-year dividend growth of 3.08% year and a payout ratio of 115.53%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Abbott Laboratories P/E ratio at 35.40 and Merck Indonesia's P/E ratio at 12.58. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Abbott Laboratories P/B ratio is 0.00 while Merck Indonesia's P/B ratio is 2.14.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Abbott Laboratories has seen a 5-year revenue growth of 0.32%, while Merck Indonesia's is 0.57%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Abbott Laboratories's ROE at 19.76% and Merck Indonesia's ROE at 16.32%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $116.33 for Abbott Laboratories and Rp3490.00 for Merck Indonesia. Over the past year, Abbott Laboratories's prices ranged from $94.50 to $121.64, with a yearly change of 28.72%. Merck Indonesia's prices fluctuated between Rp3480.00 and Rp4490.00, with a yearly change of 29.02%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.